This study explored the correlation between pretreatment serum IL-6 levels, encompassing pro-inflammatory cytokine levels, and survival outcomes in advanced pancreatic cancer patients, while also assessing how these biomarkers influence the efficacy of systemic chemotherapy. This evidence concerns the gene IL6 and pancreatic neoplasm.